ANSM completes inspection at Lupin’s Mandideep facility
6th Aug 2019

The French National Agency for Medicines and Health Products Safety (ANSM) has completed the Good Manufacturing Practices (GMP) inspection at Lupin’s finished product manufacturing facility (Unit-1) at Mandideep. The inspection was conducted between April 8, 2019 and April 12, 2019. The ANSM inspection closed with no critical or major observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.